Researcher profile · Semantic Scholar

R. Behrman

h-index: 11
Works: 20
Citations: 2,628

Most-cited papers

HIV Infection, Inflammation, Immunosenescence, and Aging
R. Behrman, R. Choudhury
2011Annual Review of Medicine1,365 citations Open access
Semantic Scholar
Developing the Sentinel System--a national resource for evidence development.
R. Behrman, J. Benner, Jeffrey S. Brown, M. Mcclellan +2 more
2011New England Journal of Medicine342 citations
Semantic Scholar
Development of novel combination therapies.
J. Woodcock, J. P. Griffin, R. Behrman
2011New England Journal of Medicine235 citations
Semantic Scholar
Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience
L. Chapman, G. Mertz, C. Peters, H. Jolson +13 more
1998Antiviral Therapy162 citations Open access
Semantic Scholar
The FDA's assessment of follow-on protein products: a historical perspective
J. Woodcock, Joseph C M Griffin, R. Behrman, B. Cherney +11 more
2007Nature reviews. Drug discovery148 citations Open access
Semantic Scholar
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
J. Englund, C. Baker, C. Raskino, R. McKinney +23 more
1997New England Journal of Medicine140 citations
Semantic Scholar
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome.
L. Chapman, B. Ellis, F. Koster, M. Sotir +15 more
2002Clinical Infectious Diseases52 citations Open access
Semantic Scholar
Economic issues with follow-on protein products
M. Lanthier, R. Behrman, C. Nardinelli
2008Nature reviews. Drug discovery50 citations
Semantic Scholar
Role of postmarketing surveillance in contemporary medicine.
J. Woodcock, R. Behrman, G. Dal Pan
2011Annual Review of Medicine48 citations
Semantic Scholar
Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective.
L. Sacks, R. Behrman
2008Tuberculosis46 citations
Semantic Scholar
Challenges, successes and hopes in the development of novel TB therapeutics.
L. Sacks, R. Behrman
2009Future Medicinal Chemistry22 citations
Semantic Scholar
TB or not TB, that is the question.
Heidi M. Jolson, R. Behrman
1992Journal of the American Medical Association (JAMA)11 citations
Semantic Scholar
FDA regulations for drug development.
R. Behrman, J. Woodcock
2010Science8 citations
Semantic Scholar
Bioinformatics Modernization and the Critical Path to Improved Benefit-Risk Assessment of Drugs
A. Oliva, R. Levin, R. Behrman, J. Woodcock
20084 citations
Semantic Scholar
Continued zidovudine or didanosine for human immunodeficiency virus infection.
R. Behrman, L. Kammerman, D. Feigal
1992New England Journal of Medicine1 citations Open access
Semantic Scholar
Mechanisms of Endocrine Resistance in Breast Cancer
J. Woodcock, R. Behrman, A. Lindsay, R. Choudhury +1 more
20150 citations
Semantic Scholar
Biosimilars: considerations for an abbreviated pathway
S. Kozlowski, R. Behrman
2009Leukemia and Lymphoma0 citations
Semantic Scholar
FDA approval of Antiretroviral Agents: An Evolving Paradigm
R. Behrman
19990 citations
Semantic Scholar
Drugs, Ageing and Society – Social & Pharmacological Perspectives.
R. Behrman
19870 citations
Semantic Scholar
Book Review: Drugs, Ageing and Society – Social & Pharmacological Perspectives
R. Behrman
19870 citations
Semantic Scholar

T. Ksiazek

×2

F. Koster×2

K. Baum×2

P. Rollin×2

R. Holman×2

J. Christenson×2

P. J. Rubin×2

G. Simpson×2